800 related articles for article (PubMed ID: 22793066)
41. Low-dose RATG with or without basiliximab in renal transplantation: a matched-cohort observational study.
Gentile G; Somma C; Gennarini A; Mastroluca D; Rota G; Lacanna F; Locatelli B; Remuzzi G; Ruggenenti P
Am J Nephrol; 2015; 41(1):16-27. PubMed ID: 25612603
[TBL] [Abstract][Full Text] [Related]
42. Tacrolimus, Mycophenolate Mofetil, and Low-Dose Steroids With or Without Interleukin-2 Receptor Antibody Induction Therapy: A Retrospective Cohort Analysis.
Schwarz C; Böhmig G; Steininger R; Unger L; Kristo I; Kozakowski N; Berlakovich GA; Soliman T; Mühlbacher F
Transplant Proc; 2015 Oct; 47(8):2446-9. PubMed ID: 26518948
[TBL] [Abstract][Full Text] [Related]
43. Induction immunosuppressive therapy in renal transplantation: does basiliximab make the difference?
Jorge S; Guerra J; Silva S; Santana A; Mil-Homens C; Prata MM
Transplant Proc; 2008 Apr; 40(3):693-6. PubMed ID: 18454989
[TBL] [Abstract][Full Text] [Related]
44. The renal-sparing efficacy of basiliximab in adult living donor liver transplantation.
Lin CC; Chuang FR; Lee CH; Wang CC; Chen YS; Liu YW; Jawan B; Chen CL
Liver Transpl; 2005 Oct; 11(10):1258-64. PubMed ID: 16184544
[TBL] [Abstract][Full Text] [Related]
45. Anti-interleukin-2 receptor antibodies for the prevention of rejection in pediatric renal transplant patients: current status.
Swiatecka-Urban A
Paediatr Drugs; 2003; 5(10):699-716. PubMed ID: 14510627
[TBL] [Abstract][Full Text] [Related]
46. Basiliximab versus daclizumab combined with triple immunosuppression in deceased donor renal graft recipients.
Grego K; Arnol M; Bren AF; Kmetec A; Tomaziĉ J; Kandus A
Transplant Proc; 2007 Dec; 39(10):3093-7. PubMed ID: 18089329
[TBL] [Abstract][Full Text] [Related]
47. A multicenter, open-label, pharmacokinetic/pharmacodynamic safety, and tolerability study of basiliximab (Simulect) in pediatric de novo renal transplant recipients.
Offner G; Broyer M; Niaudet P; Loirat C; Mentser M; Lemire J; Crocker JF; Cochat P; Clark G; Chodoff L; Korn A; Hall M
Transplantation; 2002 Oct; 74(7):961-6. PubMed ID: 12394837
[TBL] [Abstract][Full Text] [Related]
48. Reduced acute rejection and superior 1-year renal allograft survival with basiliximab in patients with diabetes mellitus. The Global Simulect Study Group.
Thistlethwaite JR; Nashan B; Hall M; Chodoff L; Lin TH
Transplantation; 2000 Sep; 70(5):784-90. PubMed ID: 11003358
[TBL] [Abstract][Full Text] [Related]
49. Triple immunosuppression with or without basiliximab in pediatric renal transplantation: acute rejection rates at one year.
Duzova A; Buyan N; Bakkaloglu M; Dalgic A; Soylemezoglu O; Besbas N; Bakkaloglu A
Transplant Proc; 2003 Dec; 35(8):2878-80. PubMed ID: 14697926
[TBL] [Abstract][Full Text] [Related]
50. Pediatric renal transplantation under tacrolimus or cyclosporine immunosuppression and basiliximab induction.
Garcia CD; Schneider L; Barros VR; Guimarães PC; Garcia VD
Transplant Proc; 2002 Nov; 34(7):2533-4. PubMed ID: 12431513
[No Abstract] [Full Text] [Related]
51. Induction treatment with rabbit antithymocyte globulin versus basiliximab in renal transplant recipients with planned early steroid withdrawal.
Martin ST; Roberts KL; Malek SK; Tullius SG; Vadivel N; De Serres S; Grafals M; Elsanjak A; Filkins BA; Chandraker A; Gabardi S
Pharmacotherapy; 2011 Jun; 31(6):566-73. PubMed ID: 21923440
[TBL] [Abstract][Full Text] [Related]
52. Basiliximab and mycophenolate mofetil in combination with low-dose cyclosporine and methylprednisolone effectively prevent acute rejection in kidney transplant recipients.
Kovac D; Kotnik V; Kandus A
Transplant Proc; 2005 Dec; 37(10):4230-4. PubMed ID: 16387086
[TBL] [Abstract][Full Text] [Related]
53. Calcineurin inhibitors in renal transplantation: what is the best option?
Tanabe K
Drugs; 2003; 63(15):1535-48. PubMed ID: 12887261
[TBL] [Abstract][Full Text] [Related]
54. Pharmacodynamic analysis of tofacitinib and basiliximab in kidney allograft recipients.
Vafadari R; Quaedackers ME; Kho MM; Mol WM; Chan G; Weimar W; Baan CC
Transplantation; 2012 Sep; 94(5):465-72. PubMed ID: 22960764
[TBL] [Abstract][Full Text] [Related]
55. Calcineurin inhibitor-free immunosuppressive strategy in elderly recipients of renal allografts from deceased donors: 1-year results from a prospective single center trial.
Arbogast HP; Hoffmann JN; Illner WD; Hillebrand GF; Fischereder M; Jauch KW; Land W
Transplant Proc; 2009; 41(6):2529-32. PubMed ID: 19715968
[TBL] [Abstract][Full Text] [Related]
56. A randomized, double-blind trial of basiliximab immunoprophylaxis plus triple therapy in kidney transplant recipients.
Ponticelli C; Yussim A; Cambi V; Legendre C; Rizzo G; Salvadori M; Kahn D; Kashi H; Salmela K; Fricke L; Heemann U; Garcia-Martinez J; Lechler R; Prestele H; Girault D;
Transplantation; 2001 Oct; 72(7):1261-7. PubMed ID: 11602853
[TBL] [Abstract][Full Text] [Related]
57. Regimen of tacrolimus-based immunosuppression with basiliximab, mycophenolate mofetil, and low-dose steroid reduces acute rejection in kidney transplants.
Hoshinaga K; Aikawa A; Murai M; Yamamoto H; Hirayama N; Shishido S; Hasegawa A
Transplant Proc; 2005 May; 37(4):1762-3. PubMed ID: 15919457
[TBL] [Abstract][Full Text] [Related]
58. Twenty-four hour steroid avoidance immunosuppressive regimen in liver transplant recipients.
Ju WQ; Guo ZY; Ling X; He XS; Wu LW; Tai Q; Hu AB; Han M; Zhu XF
Exp Clin Transplant; 2012 Jun; 10(3):258-62. PubMed ID: 22631063
[TBL] [Abstract][Full Text] [Related]
59. Histological findings of early graft biopsies in old donor renal transplant patients receiving induction therapy.
Gavela E; Pallardó LM; Sancho A; Avilla A; Beltrán S; Roselló E; Pérez ML; García F
Transplant Proc; 2009; 41(6):2099-101. PubMed ID: 19715842
[TBL] [Abstract][Full Text] [Related]
60. Rabbit antithymocyte globulin compared with basiliximab in kidney transplantation: a single-center study.
Kim JM; Jang HR; Kwon CH; Huh WS; Kim GS; Kim SJ; Joh JW; Oh HY
Transplant Proc; 2012 Jan; 44(1):167-70. PubMed ID: 22310606
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]